ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 9.65B 8.31B 7.82B 7.14B 13.36B 911B 13.39B 92.36B 35.84B 468B 36.25B 35.46B 1,507B | P/E 2026 * |
-16x | P/E 2027 * | -31.6x |
|---|---|---|---|---|---|
| Enterprise Value | 9.55B 8.22B 7.73B 7.06B 13.21B 902B 13.25B 91.37B 35.46B 463B 35.86B 35.08B 1,490B | EV / Sales 2026 * |
10.5x | EV / Sales 2027 * | 6.92x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 2012-06-30 |
Brett Monia
CEO | Chief Executive Officer | 64 | 2019-12-31 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 2000-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 2005-12-12 |
| Director/Board Member | 73 | 2002-04-30 | |
Brett Monia
BRD | Director/Board Member | 64 | 2019-03-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 9.65B | |
| -2.54% | -2.84% | -1.77% | +14.33% | 48.93B | |
| -0.40% | +1.03% | +418.57% | +527.30% | 45.01B | |
| -1.42% | +2.30% | +42.67% | +22.37% | 44.07B | |
| -1.22% | -2.31% | +4.82% | +77.49% | 40.73B | |
| +0.53% | -1.36% | +16.87% | +46.82% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +21.42% | +120.75% | 16.5B | |
| -1.01% | +0.50% | +13.91% | +31.83% | 14.67B | |
| -1.65% | -1.03% | +75.93% | +41.12% | 13.77B | |
| Average | -0.69% | +0.53% | +74.05% | +110.25% | 30.55B | |
| Weighted average by Cap. | -0.95% | +0.11% | +89.42% | +128.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 913M 786M 739M 676M 1.26B 86.24B 1.27B 8.74B 3.39B 44.24B 3.43B 3.35B 143B | 1.4B 1.21B 1.14B 1.04B 1.94B 132B 1.95B 13.42B 5.21B 67.95B 5.27B 5.15B 219B |
| Net income | -585M -503M -473M -432M -809M -55.19B -811M -5.59B -2.17B -28.32B -2.19B -2.15B -91.22B | -314M -270M -254M -232M -434M -29.61B -435M -3B -1.16B -15.19B -1.18B -1.15B -48.94B |
| Net Debt | -103M -88.66M -83.42M -76.2M -143M -9.73B -143M -986M -383M -4.99B -387M -378M -16.08B | 56.88M 48.95M 46.05M 42.07M 78.7M 5.37B 78.92M 544M 211M 2.76B 214M 209M 8.88B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
